Page last updated: 2024-12-06

4-hydroxytriamterene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-Hydroxytriamterene is a major metabolite of triamterene, a potassium-sparing diuretic. It is formed in the liver by the enzyme CYP3A4. 4-Hydroxytriamterene has been shown to have diuretic activity, but it is weaker than triamterene. It is also a potent inhibitor of the enzyme xanthine oxidase, which is involved in the metabolism of purines. This inhibition may contribute to the antihypertensive effects of triamterene. 4-Hydroxytriamterene is also a substrate for the enzyme uridine diphosphate glucuronosyltransferase, which is responsible for its detoxification and excretion. 4-Hydroxytriamterene is studied to understand its role in the metabolism of triamterene and its potential therapeutic effects. Research on this compound is ongoing, and it is not currently used clinically.'

4-hydroxytriamterene: active metabolite of triamterene; RN given refers to cpd with OH in para position [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71046
CHEMBL ID3544821
SCHEMBL ID15512756
SCHEMBL ID10537075
MeSH IDM0094453

Synonyms (21)

Synonym
4-hydroxytriamterene
p-hydroxytriamterene
4-(2,4,7-triamino-6-pteridinyl)phenol
para-hydroxytriamterene
ypp1c921ef ,
unii-ypp1c921ef
phenol, 4-(2,4,7-triamino-6-pteridinyl)-
1226-52-4
FT-0670188
4-hydroxy triamterene
4-hydroxy triamterene-d4
SCHEMBL15512756
SCHEMBL10537075
CHEMBL3544821
J-004841
AKOS030241046
DTXSID00876722
2,4,7-pteridinetriamine, 6-(4-hydroxyphenyl)-
2.4.7-triamino-6-p-hydroxyphenylpteridin
Q27294645
4-(2,4,7-triaminopteridin-6-yl)phenol

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The second study (II) assessed the bioavailability of the new product given as a single tablet on two occasions separated by an interval of 12 h compared to the full-strength product given as a single dose."( Absorption and disposition of a new low-dose combination formulation of hydrochlorothiazide and triamterene.
Benet, LZ; Blume, CD; Liang-Gee, W; Lin, ET; Williams, RL, 1990
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (81.82)18.7374
1990's1 (9.09)18.2507
2000's1 (9.09)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.60 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.16 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (9.09%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]